Needham & Company reiterates a 'Buy' rating on Regeneron Pharma (NASDAQ: REGN), PT $34 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE